Another experimental study using human receptor proteome screening indicated that camrelizumab mediated off-target binding to human receptors, such as vascular endothelial growth factor receptor 2 (VEGFR2), which might thereby drive hemangioma development via vascular endothelial cell activation (Finlay et al., 2019). The gene discussed is KDR; the disease is hemangioma.